Company: DMAC
Filing Date: 2025-03-28
Form Type: DEF 14A
Source: 0001437749-25-009696
Chunk: 68

Company: DiaMedica Therapeutics Inc.
Filing Date: 2025-03-28
Form: DEF 14A
Chunk 68
---
,787 |
| Scott Kellen                             |     |                |    39,100 |     |                  |    10,000 |
| David Wambeke                            |     |                |   150,000 |     |                  |    38,364 |
| Trill AB                                 |     |                | 4,999,999 |     |                  | 1,470,588 |
| TomEnterprise AB                         |     |                | 4,999,999 |     |                  | 1,470,588 |
| NFS/FMTC Roth IRA FBO Richard Jacinto II |     |                | 6,999,998 |     |                  | 2,058,823 |

In connection with the June 2023 private placement, we entered into a registration rights agreement with the investors pursuant to which we agreed to file with the SEC a registration statement registering the resale of the shares sold in the June 2023 private placement. The resale registration statement was filed with the SEC on June 30, 2023 and declared effective by the SEC on July 7, 2023. The registration rights agreement is substantially similar to the registration rights agreement from the June 2024 private placement described above.

On April 10, 2023, in conjunction with his appointment as Chief Business Officer of DiaMedica, Mr. David Wambeke purchased 468,750 of our common shares at an aggregate purchase price of $750,000, or $1.60 per share.

Indemnification Agreements

We have entered into indemnification agreements with all of our directors and executive officers. The indemnification agreements provide, among other things, for indemnification, to the fullest extent permitted by law and our Articles, against any and all expenses (including attorneys’ fees) and liabilities, judgments, fines and amounts paid in settlement that are paid or incurred by the executive or on his or her behalf in connection with such action, suit or proceeding. The indemnification agreements also set forth procedures that apply in the event an executive requests indemnification or an expense advance.

DiaMedica has not identified any arrangements or agreements relating to compensation provided by a third party to DiaMedica’s directors or director nominees in connection with their candidacy or board service as required to be disclosed pursuant to Nasdaq Rule 5250(b)(3).

Policies and Procedures for Related Party Transactions

The Board of Directors has delegated to the Audit Committee, pursuant to the terms of a written policy and the formal